Personalizing Cancer Drugs Trends: Market Research Report

December 2013 | 28 pages | ID: PF3CCEED3ABEN
Global Industry Analysts, Inc

Abstracts

The report illustrates that understanding of cancer is shifting from a pathology-oriented perspective to a molecular perception. Mechanisms responsible for driving cancer continue to emerge in diverse environments. In addition, the report presents an overview on the mechanism instrumental for causing some forms of breast cancer may also be responsible for promoting a subset of melanoma or brain cancer. The improved knowledge of cancer genetics is facilitating development of numerous drugs that target specific cancer cells. Cancer is one of the major chronic diseases worldwide and also the chief cause behind a huge number of fatalities. Each year, statistics post a larger figure than the previous year, indicating the rapidly growing incidence and prevalence of cancer. However, a similar pace of growth is not being reported in the area of development of drugs and therapies for treating cancers.

The report also predicts that the future holds immense promise for molecular analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with cancer treatment. Continued advances in technology are expected to lead to application of molecular analysis at each and every step in the course of cancer, ultimately enabling designing of optimal therapies, with the potential of achieving the best possible outcome, for individual patients.

Contents

1. PERSONALIZING CANCER DRUGS – A FOCUS REPORT

Personalized Medicine in Cancer Treatment – An Overview
Molecular Diagnosis and Personalized Medicine Fast Gaining Ground
Advances in Personalized Medicine in Cancer
Research for Developing Tools for Genetic Profile of Tumors
Role of Pharmacogenomics in Personalized Therapies for Cancer
Modern Personalized Medicine for Cancer – A Notch above Traditional Variant
Genomic, Proteomic, Epigenomic and Metabolomic Information to Aid Personalized Medicine in Cancer
Genomic Information for Improving Efficacy of Personalized Medicine in Cancer
Importance of Proteomic Information in Personalized Medicine for Cancer
Study of Human Epigenome Contributing to Personalized Medicine for Cancer
Metabolomics – The Latest Addition to Personalized Medicine Domain
Personalized Medicine in Diagnosis and Treatment of Breast Cancer

2. MARKET TRENDS AND ISSUES

Growing Trend towards Personalized Medicine to Fuel the Market for Cancer Diagnostics
Progressing Personalized Medicine Cancer Drugs to Clinical Stage
Need for Personalized Therapy to Go Beyond Primary Cancers
Regional Differences in Cancer Causative Factors – A Major Hindrance in Development of Cancer Therapies
Personalized Medicine in Cancer – Issues to Address
Insurance Coverage for Personalized Medicine
Participation of Healthcare Providers Key for Success of Personalized Medicine
Elimination of Regulatory Hindrances a Must
Increasing Awareness among Public for Maximizing Benefit
Scientific Barriers to Address
Recent Progress in Research
ALK Gene Inhibitors Foray into Pediatric Personalized Medicine

3. BIOMARKERS

Biomarkers for Cancer
Early Detection Biomarkers
Diagnostic Biomarkers
Prognostic Biomarkers
Predictive Biomarkers
Pharmacodynamic Biomarkers
Biomarkers - Diagnosis and Prediction of Common Cancers
Breast Cancer
Lymphoma
Colon Cancer
Leukemia
Melanoma
Lung Cancer

4. PERSONALIZED MEDICINE - AN OVERVIEW

An Introduction to Personalized Medicine
Uniqueness of DNA and Lifestyles Necessitate Personalized Medicine
Understanding Genetic Variations for Developing Better Drugs and Therapies
Molecular Analysis for Identification of Disease Sub-Groups in Polygenic Disorders
Key Benefits of Molecular Analysis of Diseases
Early Interventions and Enhanced Diagnoses
Improved Drug Development Efficiency
More Efficient Therapies
Personalized Medicine – Implications Involved
A Perfect Intellectual Property Rights System
Suitable Reimbursement Policies
Regulatory Reviews
Addressing Issues of Confidentiality, Privacy and Rights of Patients
Future Potential of Personalized Medicine

5. NOTEWORTHY MARKET PARTICIPANTS

Cell Therapeutics, Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
H3 Biomedicine, Inc. (USA)

6. REGULATORY APPROVALS

Roche Announces FDA Approval for Perjeta
Roche Receives EU Consent for Zelboraf Cancer Drug
Roche Receives FDA Approval for Zelboraf Cancer Drug
Roche Obtains EU Approval for Tarceva

7. PRODUCT LAUNCHES

Pfizer Canada Launches XALKORI
bioTheranostics Introduces New Line of “PRECIS” Biomarkers Series

8. CORPORATE INITIATIVES

AlacrisTheranostics Inks Pact with GlaxoSmithKline

4SC DISCOVERY OBTAINS GRANT FOR DEVELOPING NEW PERSONALIZED CANCER DRUGS

Merrimack Enters into a Partnership with CTCA
Genomic Health Forms Strategic Alliance with OncoMed
Epizyme Enters into Partnership with Celgene for Advancing MLL Therapy
Abbott Expands Personalized Medicine Alliance with GSK
QIAGEN Inks Pact with Pfizer for Developing Companion Diagnostic
Blueprint Plans to Create Genomics-based Cancer Drugs
H3 Biomedicine Commences R&D Operations for Innovative Cancer Treatments
H3 Biomedicine Receives Research Funding from Eisai

9. APPENDIX